All Clarivate websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.
As the demand increases for ventilators to treat Americans with severe symptoms of COVID-19, another shortage is being exacerbated – a shortage of the drugs needed to treat patients on ventilators.
LONDON – COVID-19 is posing a real threat to the viability of medical charities in the U.K., which collectively fund 17,000 scientists and invest more than £1.3 billion (US$1.6 billion) per annum in research.
With nearly a quarter of the activity announced in March focused on COVID-19, the first quarter of 2020 appears to be on target to beat the deal and M&A values of two of the last three years, although it remains behind 2019. Despite the uncertainty of the coronavirus pandemic, let alone the upcoming U.S. presidential election, the industry has fared relatively well in terms of dealmaking so far this year, even as the markets have plummeted and partnering events have moved to a virtual format. In fact, deals should logically increase as the pandemic takes its toll on the economy, according to a biopharma executive who responded to a recent J.P. Morgan survey.
Many adaptations to the coronavirus pandemic will remain standard features of health care long after the pandemic wanes, according to Brian Chapman, managing partner at ZS Associates, an Evanston, Ill.-based pharmaceutical and medical technology consultancy. In the long term, telehealth will be a clear winner as payers look to lower ongoing costs, more procedures and care will move out of hospitals, rapid diagnostics will gain importance, and government and payer coverage of infectious disease testing of all kinds will expand, he predicted.
The emergence of the new variety of coronavirus has had a massive effect on medical care across the globe, which has boosted telehealth coverage while suppressing non-emergency procedures. Several medical societies have published guidelines for procedures during the COVID-19 outbreak, however, which in the aggregate suggest that many procedures will be significantly delayed.
Keeping you up to date on recent developments in cardiology, including: Patient data registry aims to give insights for care, adverse cardiovascular outcomes; Research: Medicare changes could boost TAVR access; Muscle protein serves essential role in blood clotting during heart attack.
Although public offerings slowed considerably in March as a result of the steepest stock market declines in history during that period, global biopharmaceutical companies managed to collectively generate just over $16 billion in the first quarter from a record number public and private transactions. Only the first quarter of 2018 saw more cash raised in the past decade, according to BioWorld data.
RSS
